Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2

Hongzhi Chen (chenhongzhi2013@csu.edu.cn)  
Central South University

Lingli Tang  
Central South University

Xinling Yu  
Hunan Institute of Parasite Disease

Jie Zhou  
Hunan Institute of Parasite Disease

Yunfeng Chang  
Central South University

Xiang Wu  
Central South University

Short Report

Keywords: SARS-CoV-2, Epitope, Vaccine, Bioinformatics

DOI: https://doi.org/10.21203/rs.3.rs-24655/v2

License: ☇ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: An outbreak of infection caused by SARS-CoV-2 recently has brought a great challenge to public health. Rapid identification of immune epitopes would be an efficient way to screen the candidates for vaccine development at the time of pandemic. This study aimed to predict the protective epitopes with bioinformatics methods and resources for vaccine development.

Methods: ABCpred and BepiPred servers were utilized for sequential B-cell epitope analysis. Discontinuous B-cell epitopes were predicted via DiscoTope 2.0 program. IEDB server was utilized for HLA-1 and HLA-2 binding peptides computation. Surface accessibility, antigenicity, and other important features of forecasted epitopes were characterized for immunogen potential evaluation.

Results: A total of 63 sequential B-cell epitopes on spike protein were predicted and 4 peptides (Spike 315-324, Spike 333-338, Spike 648-663, Spike 1064-1079) exhibited high antigenicity score and good surface accessibility. 10 residues within spike protein (Gly 496, Glu 498, Pro 499, Thr 500, Leu 1141, Gln 1142, Pro 1143, Glu 1144, Leu 1145, Asp 1146) are forecasted as components of discontinuous B-cell epitopes. The bioinformatics analysis of HLA binding peptides within nucleocapsid protein produced 81 and 64 peptides being able to bind MHC class I and MHC class II molecule respectively. The peptides (Nucleocapsid 66-75, Nucleocapsid 104-112) were predicted to bind a wide spectrum of both HLA-1 and HLA-2 molecules.

Conclusions: B-cell epitopes on spike protein and T-cell epitopes within nucleocapsid protein were identified and recommended for developing a protective vaccine against SARS-CoV-2.

Background

An outbreak of infection caused by a novel coronavirus has spread worldwide rapidly [1, 2]. The WHO named the disease COVID-19, short for “coronavirus disease 2019”. As of 27 May 2020, the WHO reported a total of 5,488,825 COVID-19 cases and 349,095 deaths globally (WHO COVID-2019 Situation report-128), which brought a great challenge to public health worldwide. Therefore, it is imminent to prevent and control this infectious disease.

The pathogen causing the new type of pneumonia was named SARS-CoV-2 by the Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses[3]. Its genome sequence has been released and reported by Chinese scientists and submitted to the GenBank database on 12 January 2020[4]. Like SARS-CoV and MERS-CoV, the other two viruses that caused severe epidemic problems in recent years, SARS-CoV-2 also belongs to β-coronaviruses family. Bats are proved to be their natural host[5]. At present, insufficient knowledge of the latency and contagiosity of SARS-CoV-2 increased the uncertainty of virus persistency. Specific therapeutic agents targeting the virus are currently not available. Vaccination is still the most economic and effective approach to prevent virus infection. The selection and design of protective immunogens against pathogens is a major challenge in vaccine development, especially for the newly emerging pathogens[6, 7]. Traditional methods based on lab experiments could
not meet the needs of the pressing situation in the event of an outbreak[8]. Bioinformatics is an interdisciplinary field specialized in organizing, storing, and processing large amounts of data generated from biological experiments. Accumulation of large-scale immunological data gave rise to the field known as immunoinformatics, which provides insights into the mechanisms of immune function. As the genome and protein sequence information of SARS-CoV-2 is available, characteristics of the virus, as well as the epitopes presented in the pathogen, could be predicted by in silico analysis, which will greatly speed up the vaccine development[9-11].

The purpose of this study is to predict B-cell epitopes on spike protein and T-cell epitopes within nucleocapsid protein of SARS-CoV-2 by applying the bioinformatics methods and immunoinformatic tools. The step-by-step procedure of in silico analysis is depicted in Figure 1. Epitopes information presented by this work may aid in developing a promising vaccine against SARS-CoV-2.

Methods

Data retrieval and sequence alignment

Protein sequences of SARS-CoV-2 were retrieved from the NCBI database. Clustal Omega is the current standard version of the Clustal family which was widely used for biological sequences alignment. The program uses seeded guide trees and Hidden Markov model engine to generate alignments[12]. In this study, alignment of protein sequences was performed on the EMBL-EBI server with Clustal Omega program. Conserved domains within predicted polypeptides of SARS-CoV-2 were analyzed with CD-search on the NCBI website.

Linear B-cell epitope prediction

ABCpred[13] and BepiPred[14] servers were employed for B-cell epitope forecast. We used a threshold value of 0.85 to achieve a sensitivity between 95.5% and 99.5% for epitope prediction on ABCpred server[13]. The length of linear B-cell epitopes normally varies from 5 to 30 residues. In this study, we used the default window length of 16 to obtain the maximum accuracy of prediction[13]. Predicted epitopes were highlighted as sphere in SARS-CoV-2 spike protein structure viewed by the pymol molecular graphics system. Surface accessibility of predicted peptides was evaluated with the recently resolved protein structure [15]. We utilized vaxijen2.0 server to analyze the antigenicity of chosen epitopes[16].

Discontinuous B-cell epitope prediction

Prediction of discontinuous epitopes on spike protein (PDB ID: 6VSB chain B) was conducted via DiscoTope 2.0 server[17]. The parameter was set at -1.0 which indicates 85% specificity and 30% sensitivity. This method is based on surface accessibility, residue statistics, and spatial information in a compiled data set of discontinuous epitopes discovered by X-ray crystallography of antigen/antibody complex structure. The contact number, propensity score, and disctope score for each amino acid are provided for conformation-based epitope prediction. Pymol was employed to illustrate the position of predicted epitopes on the 3D structure of SARS-CoV-2 spike protein recently resolved[15].
**T-cell epitope prediction**

We used the free online service provided by IEDB to forecast T-cell epitopes within nucleocapsid protein binding to HLA-1[18] or HLA-2[19] molecule. A relatively small pool of HLA alleles covering the majority of the population, over 97% and 99% for class-I and class-II respectively, were chosen in the analysis[20, 21]. The sequences were given in plain format and the top 50% scoring peptides were retained for further analysis.

**Profiling and evaluation of predicted T-cell epitopes**

Key features including digestion, mutation, toxicity, allergenicity, hydro and physiochemical properties were analyzed via vaxijen 2.0[16], protein digest server[11], AllerTOP v2.0 server[22], and ToxinPred server[23]. Immunogenicity of predicted HLA-1 binding peptides was assessed by the Class-I Immunogenicity service provided on IEDB.

**Results**

**Protein coding features of SARS-CoV-2 genome**

A map of the predicted ORFs is depicted in Supplementary Figure 1 based on the genome sequence of the virus Wuhan-Hu-1 isolate (NCBI Reference Sequence number: NC_045512.2). The genomic structure of SARS-CoV-2 shares characteristics that are also found in other coronaviruses including SARS-CoV, MERS-CoV, and HCoV-NL63. All these coronaviruses contain recognizable ORFs including the replicase (orf1ab polyprotein), surface glycoprotein (spike protein), envelope protein, membrane glycoprotein, nucleocapsid protein, and several non-structure proteins (NSP). The conserved domains of proteins encoded by the SARS-CoV-2 genome are summarized in Supplementary Table 1. Spike protein mediates the specific binding of the virion to the receptor on the host cell membrane. The overall structure of spike protein is outside the virus particle[15]. Thus, it is an ideal target for B-cell epitope screening. Compared to spike protein, nucleocapsid protein is more conserved in selected coronaviruses (Figure 2). Though unable to induce humoral immunity, nucleocapsid protein in SARS-CoV and MERS-CoV has been experimentally tested as a robust immunogen to induce cytotoxic T-lymphocyte (CTL)-mediated response[24, 25], which suggests nucleocapsid protein in SARS-CoV-2 could be a good candidate for T-cell epitope prediction.

**Sequence analysis of spike protein and nucleocapsid protein in selected coronaviruses**

To better understand the characteristic of SARS-CoV-2, we compared its protein sequences with other selected coronaviruses. All protein sequences were downloaded from NCBI database with accession IDs shown in Figure 2A. The total sequence identity and phylogenetic tree results were presented in Figure 2B&2C. Consistent with a recently published study[26], we found that both spike and nucleocapside proteins in SARS-CoV-2 are more closely related to that of SARS-CoV. The protein domains of spike and nucleocapsid proteins (Figure 2D) were depicted based on previous studies on SARS-CoV[27, 28] and the protein alignment result in the current study (supplementary file S1 and supplementary file S2). The amino acid sequence identity result confirmed a high similarity between SARS-CoV-2 and SARS-CoV. As
anticipated, the nucleocapsid protein is more conserved among selected coronaviruses compared to spike protein.

**B-cell epitopes recognition**

The full-length sequence of spike protein was scanned for putative sequential B-cell epitopes by two types of bioinformatics programs. A total of 28 non-overlapping peptides were identified by ABCpred server with the threshold set at 0.85 (Supplementary Table 2). For sequential B-cell epitopes prediction on BepiPred-2.0 server, a threshold value of 0.5 was applied and 35 peptides were predicted (Supplementary Table 3). Antigenicity was calculated by Vaxijen 2.0 server and peptides with the highest antigenicity scores were selected (Tables 1&2). The structure of SARS-CoV-2 spike protein was resolved recently with Cryo-electron microscopy (cryo-EM) [15], which could greatly facilitate the process of vaccine development. Predicted epitopes in Tables 1&2 were highlighted as sphere in monomer structure of spike protein viewed with pymol (Supplementary Figure 2). While most epitopes predicted were exposed on the surface of spike monomer, only epitopes Spike315-324(TSNFRVQPT), Spike333-338(TNLCPF), Spike648-663(GCLIGAEHVNSYEC), Spike1064-1079(HVTYVPAQNEKTAP) displayed good surface accessibility in spike trimer (Figure 3 and Supplementary File: B-cell-epitope-animation.ppt), the pattern more likely exists in nature. Conformation-based B-cell epitopes were computed on DiscoTope 2.0 server [17]. A threshold value of -1.0 was chosen for the computation, which corresponds to a specificity of 85% and a sensitivity of 30%. The contact number, propensity score, and disctope score for each amino acid that passed the threshold were presented in Table 3. The position of these residues was viewed with pymol and highlighted as sphere (Figure 4). Processing with a combination of B-cell epitope scanning and peptide analysis forecasted 4 potent linear epitopes and 10 residues involved in discontinuous epitopes formation.

**T-cell epitopes recognition**

In our study, the IEDB server was utilized following prediction methods recommended (a combination of ANN, SMM, CombLib, and NetMHCpan EL methods for HLA-1 binding prediction, and a combination of NN-align, SMM-align, CombLib, Sturniolo, and NetMHCIIpan methods for HLA-2 binding prediction).

For HLA-1 binding peptide prediction, the top 50% scoring peptides were retained for further analysis. A total of 81 nonrepetitive peptides with ANN_IC50 value not higher than 500, indicative of stronger than medium binding affinity, were identified (Supplementary Table 4). 6 peptides with the highest antigenicity scores by vaxijen 2.0 were chosen for next step processing. In this step, we screened all HLA-1 molecules being able to bind these peptides (Table 4). A similar strategy was applied for HLA-2 binding peptides prediction on the IEDB server and 64 peptides were identified as HLA-2 binding sequences (Supplementary Table 5). 6 peptides with the highest antigenicity scores were selected for HLA-2 molecule screening and the result was presented in Table 5. In the selected peptides pool for HLA binding, Nucleocapsid104-112(LSPRWYFYY) was predicted as both HLA class-I and class-II binding peptides. Additionally, this peptide may excel in the capability of binding to a large number of HLA molecules as shown in Tables
A partially overlapping region was found in the CTL epitope \text{Nucleocapsid}_{66-74} (FPRGQGVPI) and the helper T-lymphocyte (Th) epitope \text{Nucleocapsid}_{67-75} (PRGQGVPIN), which suggests the sequence containing these two epitopes may initiate both CD4\(^+\) and CD8\(^+\) dependent immune response.

**Selected T-cell epitopes feature profiling and evaluation**

Peptide stability, mutation analysis, toxicity, allergenicity, hydro and physiochemical features were calculated and the results were presented in Supplementary Table 6. While no peptide listed is toxic, a majority of them are potentially allergenic. To forecast the probability of an immune response induced by the predicted HLA-1 binding peptides, the Class-I Immunogenicity test was performed and the scores were presented in Table 6. A higher score indicates a higher potential of immune response induction.

**Peptides selected and multi-epitope based vaccine design**

To induce humoral and cellular immune response simultaneously, five peptides that contain four linear B-cell epitopes and three T-cell epitopes (Figure 5A) were selected for vaccine development. To facilitate the processing of the T-cell epitopes, selected peptides from nucleocapsid protein were extended 5 amino acid residues at both N- and C-terminus as compared to the predicted epitopes. These peptides were scanned on the IEDB database. We found that five sequences presented in the vaccine construct were identical to the experimentally verified epitopes on SARS-CoV. These determined peptides displayed a strong or medium binding affinity to a series of MHC molecules (Supplementary Table 7). These epitopes likely possess cross-protective effects against SARS-CoV-2 as well. As shown in Figure 5B, peptides selected in this study were joined together by using GPGPG and (GGGGS)\(_2\) linkers. The Pan DR epitope (PADRE), a universal Th epitope that activates CD4\(^+\) cells[29], was introduced at the N terminus of the vaccine construct to enhance helper T cell activity. The vaccine construct can be generated as previously reported[30, 31].

**Discussion**

Different from the less harmful human coronaviruses continuously circulating in the human population, coronaviruses originated from animals could become fatal pathogens by crossing species barriers. SARS-CoV in 2003, MERS-CoV since 2012, and SARS-CoV-2 right now all have caused large-scale epidemic problems. Effective and economic preventive approaches are in need urgently at the current situation of pandemic.

Compared to traditional vaccine development, potent epitopes can be predicted via bioinformatics analysis, which makes the vaccine design straightforward and fast[32]. As the majority of spike protein is exposed outside the virion, it could be an ideal target to search for B-cell epitopes. Spike proteins in MERS-CoV and SARS-CoV have been shown to induce robust immune response[33, 34]. Dr. Baruah and Dr. Bose’s study also indicated that epitopes on spike protein could be promising candidates for SARS-CoV-2 vaccine development[35]. In another study, the experimentally determined epitopes derived from SARS-CoV were screened and those harboring the same sequence in SARS-CoV-2 were identified [36]. Similar strategy was
followed in Grifoni’s study [37]. Though the SARS-CoV-2 spike protein displayed 77.38% sequence identity toward that of SARS-CoV, most of the antibodies against SARS-CoV spike protein showed poor cross-reactivity with that of SARS-CoV-2 [38], which indicates the spike proteins have significantly variable structure. Thus, we applied distinct strategy and evaluated the surface accessibility of predicted B-cell epitopes to exclude those buried inside the protein. Though we utilized similar bioinformatics tools and resources, the peptides we selected for vaccine development are not alike. In our analysis of SARS-CoV-2 spike protein, four peptides identified from multi-step screening displayed excellent surface accessibility. The peptide Spike\textsubscript{333-338} produces a random coil structure and has a high antigenicity score. Noticeably, this peptide sits in the receptor-binding domain (RBD) of spike protein of SARS-CoV-2, which has been proved to mediate the binding to ACE2 on the epithelial membrane of human lungs[39]. Likely, antibodies recognizing this epitope could also neutralize the virus and prevent infection. The epitope Spike\textsubscript{648-663} predicted in this study is 12 amino acids upstream of the furin cleavage site which is critical for SARS-CoV-2 biogenesis [40]. We expect that an antibody recognizing the epitope Spike\textsubscript{648-663} could have expanded therapeutic function.

Besides B-cell epitope prediction on spike protein, we selected nucleocapsid protein as a target protein for T-cell epitope computation for the following reasons: First, nucleocapsid protein in SARS-CoV and MERS-CoV has been experimentally tested as a robust immunogen to induce cytotoxic T lymphocyte response[24, 25]; Second, nucleocapsid protein is the predominant protein expressed in the virion during the early stage of infection[41]; Third, nucleocapsid protein was detected in the majority of SARS-CoV infected patients as early as day 1 of infection[42, 43], which suggests nucleocapsid protein-based vaccine may evoke T-cell dependent immune response timely. 81 and 64 peptides within nucleocapsid protein were predicted to bind HLA-1 and HLA-2 molecules respectively. The peptide Nucleocapsid\textsubscript{104-112} showed an immunogenicity score of 0.36, suggesting a capability to initiate a strong immune response. Moreover, the peptides Nucleocapsid\textsubscript{104-112} and Nucleocapsid\textsubscript{66-75} harbor experimentally determined epitopes that bind to a number of HLA-1 molecules. In this study, Nucleocapsid\textsubscript{104-112} and Nucleocapsid\textsubscript{66-75} are forecasted as multi-epitopes that bind to both HLA-1 and HLA-2 molecules, suggesting a potency of both CTL and Th-mediated immune response initiation. Though these peptides were predicted to be non-toxic, we noticed that a large number of these peptides could be allergens. Thus, special attention should be paid to potential allergic reactions during the pre-clinical and clinical trials. As nucleocapsid protein is highly conserved between SARS-CoV-2 and SARS-CoV, available information on nucleocapsid protein-based vaccine against SARS-CoV could be helpful.

The final vaccine construct comprising of CTL, Th, and B-cell epitopes is predicted to initiate protective humoral and cellular immune response against SARS-CoV-2.

Conclusions

B-cell epitopes on spike protein and T-cell epitopes on nucleocapsid protein were predicted and analyzed in the current study. A total of 63 linear B-cell epitopes on spike protein were forecasted by ABCpred and BepiPred servers. 10 residues within spike protein (Gly\textsuperscript{496}, Glu\textsuperscript{498}, Pro\textsuperscript{499}, Thr\textsuperscript{500}, Leu\textsuperscript{1141}, Gln\textsuperscript{1142}, Pro\textsuperscript{1143},...
Glu\textsuperscript{1144}, Leu\textsuperscript{1145}, Asp\textsuperscript{1146}) were forecasted by DiscoTope 2.0 program as components of conformational B-cell epitopes. IEDB server was used for T-cell epitopes prediction, which gave rise to 81 and 64 peptides with binding capability to class-I and class-II molecule respectively. 4 B-cell epitopes: Spike\textsubscript{315-324}(TSNFRVQPT), Spike\textsubscript{648-663}(GCLIGAEHVNNSYECD), Spike\textsubscript{1064-1079}(HVTYVPAQEKNTTAP), and Spike\textsubscript{333-338}(TNLCPF) were selected from the list based on their antigenicity score and surface accessibility. The T-cell epitopes Nucleocapsid\textsubscript{104-112}(LSPRWYFYY) and Nucleocapsid\textsubscript{66-75}(FPRGQGVPIN) on nucleocapsid protein could bind a wide spectrum of both HLA-1 and HLA-2 molecules. The final vaccine construct consists of CTL, Th, and B-cell epitopes that potentially protect individuals against SARS-CoV-2 by inducing both humoral and cellular immune response, which should be successively validated within both \textit{in vitro} and \textit{in vivo} models.

**Declarations**

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

All presentation of the data have consent for publication.

**Availability of data and materials**

All analyzed data of this study are included with the manuscript and its supplementary information files.

**Competing interests**

The authors declare no conflict of interests

**Funding**

This work was supported by Changsha Municipal Science and Technology Bureau Emergency Program on COVID-19, the National Science Fundation of China [No. 81970746, No.81371834, No. 81828004, and No. 81820108007], Hunan Provincial Natural Sciences Foundation [No. 2018JJ3740], and Major Science and Technology Project of Hunan Province [No. 2017SK1020].
Acknowledgements

We appreciate the generous technical support from Dr. Ning Zhang.

Authors’ contributions

HC and XW performed bioinformatics analysis of epitope prediction. HC wrote the first draft of the manuscript. YC, LT, JZ, and XY revised the manuscript. XW was responsible for the final approval of the manuscript.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395(10223):497-506.
2. Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS: The 2019 novel coronavirus disease (COVID-19) pandemic: A zoonotic prospective. Asian Pacific Journal of Tropical Medicine 2020. Epub ahead of print. DOI: 10.4103/1995-7645.281613
3. Coronaviridae Study Group of the International Committee on Taxonomy of V: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020, 5(4):536-544.
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al: A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020, 382(8):727-733.
5. Ceraolo C, Giorgi FM: Genomic variance of the 2019-nCoV coronavirus. J Med Virol 2020.
6. Qiu T, Yang Y, Qiu J, Huang Y, Xu T, Xiao H, Wu D, Zhang Q, Zhou C, Zhang X et al: CE-BLAST makes it possible to compute antigenic similarity for newly emerging pathogens. Nat Commun 2018, 9(1):1772.
7. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS: SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci 2020, 24(7):4016-4026.
8. Rauch S, Jasny E, Schmidt KE, Petsch B: New Vaccine Technologies to Combat Outbreak Situations. Front Immunol 2018, 9:1963.
9. Tahir Ul Qamar M, Bari A, Adeel MM, Maryam A, Ashfaq UA, Du X, Muneer I, Ahmad HI, Wang J: Peptide vaccine against chikungunya virus: immuno-informatics combined with molecular docking approach. J Transl Med 2018, 16(1):298.
10. Ahmad B, Ashfaq UA, Rahman MU, Masoud MS, Yousaf MZ: Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach. Microb Pathog 2019, 132:243-253.
11. Tahir Ul Qamar M, Saleem S, Ashfaq UA, Bari A, Anwar F, Alqahtani S: Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study. *J Transl Med* 2019, 17(1):362.

12. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, Basutkar P, Tivey ARN, Potter SC, Finn RD *et al*.: The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res* 2019, 47(W1):W636-W641.

13. Saha S, Raghava GP: Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. *Proteins* 2006, 65(1):40-48.

14. Jespersen MC, Peters B, Nielsen M, Marcatili P: BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. *Nucleic Acids Res* 2017, 45(W1):W24-W29.

15. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020, 367(6483):1260-1263.

16. Doytchinova IA, Flower DR: VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. *BMC Bioinformatics* 2007, 8:4.

17. Kringelum JV, Lundegaard C, Lund O, Nielsen M: Reliable B cell epitope predictions: impacts of method development and improved benchmarking. *PLoS Comput Biol* 2012, 8(12):e1002829.

18. Andreatta M, Nielsen M: Gapped sequence alignment using artificial neural networks: application to the MHC class I system. *Bioinformatics* 2016, 32(4):511-517.

19. Nielsen M, Lundegaard C, Lund O: Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. *BMC Bioinformatics* 2007, 8:238.

20. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, de Silva AD, de Silva AM *et al*.: Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. *Proc Natl Acad Sci U S A* 2013, 110(22):E2046-2053.

21. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A: Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. *Immunogenetics* 2011, 63(6):325-335.

22. Dimitrov I, Flower DR, Doytchinova I: AllerTOP--a server for in silico prediction of allergens. *BMC Bioinformatics* 2013, 14 Suppl 6:S4.

23. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GP: Peptide toxicity prediction. *Methods Mol Biol* 2015, 1268:143-157.

24. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL: Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci U S A* 2004, 101(26):9804-9809.

25. Veit S, Jany S, Fux R, Sutter G, Volz A: CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice. *Viruses* 2018, 10(12).
26. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020, 9(1):221-236.

27. Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, Wang X: Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 2017, 27(1):119-129.

28. Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH: The SARS coronavirus nucleocapsid protein–forms and functions. Antiviral Res 2014, 103:39-50.

29. Alexander J, del Guercio MF, Frame B, Maewal A, Sette A, Nahm MH, Newman MJ: Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine 2004, 22(19):2362-2367.

30. Chauhan V, Rungta T, Goyal K, Singh MP: Designing a multi-epitope based vaccine to combat Kaposi Sarcoma utilizing immunoinformatics approach. Sci Rep 2019, 9(1):2517.

31. Khan M, Khan S, Ali A, Akbar H, Sayaf AM, Khan A, Wei DQ: Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Sci Rep 2019, 9(1):13321.

32. Rappuoli R, Bottomley MJ, D’Oro U, Finco O, De Gregorio E: Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 2016, 213(4):469-481.

33. Zhou Y, Jiang S, Du L: Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines 2018, 17(8):677-686.

34. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY et al: Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008, 180(2):948-956.

35. Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, Lee SS, Chakraborty C: Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. J Med Virol 2020.

36. Ahmed SF, Quadeer AA, McKay MR: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 2020, 12(3).

37. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A: A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe 2020.

38. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y et al: Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020, 9(1):382-385.
39. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL et al: *A pneumonia outbreak associated with a new coronavirus of probable bat origin*. Nature 2020.

40. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D: *Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein*. Cell 2020.

41. Surjit M, Lal SK: *The SARS-CoV nucleocapsid protein: a protein with multifarious activities*. Infect Genet Evol 2008, 8(4):397-405.

42. Che XY, Hao W, Wang Y, Di B, Yin K, Xu YC, Feng CS, Wan ZY, Cheng VC, Yuen KY: *Nucleocapsid protein as early diagnostic marker for SARS*. Emerg Infect Dis 2004, 10(11):1947-1949.

43. Li YH, Li J, Liu XE, Wang L, Li T, Zhou YH, Zhuang H: *Detection of the nucleocapsid protein of severe acute respiratory syndrome coronavirus in serum: comparison with results of other viral markers*. J Virol Methods 2005, 130(1-2):45-50.

**Tables**

Table 1  B-cell epitope predicted via ABCpred server are presented along with their position and antigenicity scores

| ABCpred | Position | Epitope sequence | Score | Antigenicity |
|---------|----------|------------------|-------|--------------|
| Spike   | 406-421  | EVRQIAPG QTGKIADY | 0.85  | 1.3837       |
|         | 648-663  | GCLIGAEH VNNSYECD | 0.90  | 0.8480       |
|         | 898-913  | FAMQMAY RFNGIGVTQ | 0.88  | 1.3096       |
|         | 1058-1073| HGVVFLH VTYVPAQEK | 0.89  | 0.8847       |
|         | 1064-1079| HVTYVPA QEKNFTTAP | 0.88  | 0.8933       |
|         | 1206-1221| YEQYIKWP WYIWLGF | 0.89  | 0.9510       |

Table 2  B-cell epitope predicted via BepiPred server are presented along with their position and antigenicity scores
| BepiPred | Position | Epitope sequence | Antigenicity |
|----------|----------|-----------------|-------------|
| Spike    | 315-324  | TSNFRVQPT       | 1.3571      |
|          | 333-338  | TNLCPF          | 1.2508      |
|          | 372-397  | ASFSTFKCYGVSPTKLNDLCFTNVYA | 1.2880 |
|          | 406-426  | EVRQIAPGQTGKIADYNKLP | 1.3005 |
|          | 1037-1045| SKRVDFCGK       | 1.7321      |
|          | 1204-1209| GKYEQY         | 1.2821      |

Table 3  Discontinuous B-cell epitopes predicted through DiscoTope 2.0 server

| Residue position | Residues name | Contact number | Propensit y score | Discotope score |
|------------------|---------------|----------------|-------------------|----------------|
| 496              | GLY           | 1              | -0.693            | -0.728         |
| 498              | GLN           | 7              | 1.188             | 0.246          |
| 499              | PRO           | 5              | 0.294             | -0.315         |
| 500              | THR           | 1              | 2.231             | 1.860          |
| 1141             | LEU           | 5              | -0.017            | -0.59          |
| 1142             | GLN           | 7              | 0.372             | -0.476         |
| 1143             | PRO           | 6              | 0.629             | -0.134         |
| 1144             | GLU           | 4              | 0.704             | 0.163          |
| 1145             | LEU           | 5              | 0.171             | -0.424         |
| 1146             | ASP           | 4              | 0.724             | 0.181          |

Table 4  HLA class-I alleles binding epitopes predicted by IEDB server
| Peptides     | Position | HLA class-I alleles | Vaxijen score |
|-------------|----------|---------------------|---------------|
| LSPRWYFYY   | 104-112  | HLA-A*0101, HLA-A*3002, HLA-B*5701, HLA-A*1101, HLA-A*2601, HLA-B*5801, HLA-A*2402, HLA-A*3101, HLA-B*3501, HLA-B*1501, HLA-A*0301, HLA-A*6801 | 1.2832 |
| RSRNNSRNS   | 189-197  | HLA-A*3001          | 1.1144        |
| IGYYRRATR   | 84-92    | HLA-A*3101, HLA-A*3301, HLA-A*6801, HLA-A*0301, HLA-A*3001 | 0.8880        |
| FTALTQHGK   | 53-61    | HLA-A*6801, HLA-A*1101, HLA-A*0301, HLA-A*0101, HLA-A*3001, HLA-A*3101 | 0.8510        |
| KSAAEASKK   | 249-257  | HLA-A*0301, HLA-A*1101, HLA-A*3001, HLA-A*6801, HLA-A*3101 | 0.7679        |
| FPRGQGVPI   | 66-74    | HLA-B*0702, HLA-B*5101, HLA-B*5301, HLA-B*0801, HLA-B*3501 | 0.7585        |

Table 5  HLA class-II alleles binding epitopes predicted by IEDB server
| Peptides       | Position | HLA class-II alleles                                                                 | Vaxijen score |
|---------------|----------|--------------------------------------------------------------------------------------|---------------|
| IKLDDKDPN     | 337-345  | DRB1_0701,DRB1_0301,DRB3_01,DRB1_0405,DPRB1_1101,DPB1_0402,DQA1_01,DRB1_0501,DRB1_0901,DPA1_0103/DPB1_0201 | 2.3118        |
| RSGARSKQR     | 32-40    | DRB5_0101,DRB4_0101,DQA1_0501/DQB1_0301                                              | 1.7874        |
| RIGMEVTPS     | 319-327  | DRB1_1101,DRB1_0401,DQA1_0102/DQB1_0602,DRB1_0802,DRB1_0301,DPA1_0301/DPB1_0402,DPRB1_0101,DQA1_0501/DQB1_0103 | 1.5314        |
| RGTSPARMA     | 203-211  | DQA1_0501/DQB1_0102,DRB1_0901                                                        | 1.2953        |
| LSPRWYFYY     | 104-112  | DRB1_0405,DQA1_0101/DQB1_0501,DPA1_0103/DPB1_0201,DRB1_1201,DPRB1_1302,DPA1_0201/DPB1_0101 | 1.2832        |
Table 6  Class-I immunogenicity

| Peptides     | Position | class-I Immunogenicity |
|--------------|----------|------------------------|
| LSPRWYFY     | 104-112  | 0.35734                |
| RSRNSSR      | 189-197  | 0.1499                 |
| IGGYRRAT     | 84-92    | -0.00164               |
| FALTQHGK     | 53-61    | -0.0226                |
| KSAAEASKK    | 249-257  | -0.07922               |
| FPRGQGVPI    | 66-74    | -0.26664               |

Figures
Figure 1

Study workflow. Suitable proteins of SARS-CoV-2 were selected at the first step for epitope prediction. The second step comprised of B- and T-cell epitope analysis with bioinformatics approaches. Epitope evaluation was followed and appropriate ones were chosen for vaccine design.
### Table A

| Coronavirus  | Spike protein | Nucleocapsid protein |
|--------------|---------------|----------------------|
| SARS-CoV-2   | YP_009724390  | YP_009724397         |
| SARS-CoV     | NP_828851     | NP_828858            |
| MERS-CoV     | YP_009047204  | YP_009047211         |
| HCoV-NL63    | AFV53148      | AFV53152             |

### Table B

| Sequence identity compared to SARS-CoV-2 | Spike protein | Nucleocapsid protein |
|------------------------------------------|---------------|----------------------|
| SARS-CoV                                 | 77.38%        | 89.74%               |
| MERS-CoV                                 | 31.93%        | 45.59%               |
| HCoV-NL63                                | 27.46%        | 29.03%               |

### Diagram C

**Spike protein**
- HCoV-NL63 (0.39579)
- MERS-CoV (0.34598)
- SARS-CoV-2 (0.11223)
- SARS-CoV (0.11339)

**Nucleocapsid protein**
- HCoV-NL63 (0.45272)
- MERS-CoV (0.26197)
- SARS-CoV-2 (0.05176)
- SARS-CoV (0.05086)

### Diagram D

#### Spike protein:

- SARS-CoV-2: 1
  - NTD
  - RBD
  - SD
  - S2
  - CT
  - 1273
- SARS-CoV: 1
  - NTD
  - RBD
  - SD
  - S2
  - CT
  - 1255
- MERS-CoV: 1
  - NTD
  - RBD
  - SD
  - S2
  - CT
  - 1353
- HCoV-NL63: 1
  - NTD
  - RBD
  - SD
  - S2
  - CT
  - 1356

#### Nucleocapsid protein:

- SARS-CoV-2: 1
  - NTD
  - LKR
  - CTD
  - 419
- SARS-CoV: 1
  - NTD
  - LKR
  - CTD
  - 422
- MERS-CoV: 1
  - NTD
  - LKR
  - CTD
  - 413
- HCoV-NL63: 1
  - NTD
  - LKR
  - CTD
  - 377

**Sequence identity:**
- 90%
- 10%
Figure 2

Spike and nucleocapsid protein in selected coronaviruses
A. Accession IDs of spike protein and nucleocapsid protein in selected coronavirus
B. Sequence identity of spike protein and nucleocapsid protein among selected coronavirus
C. Phylogenetic analysis of target proteins of selected coronaviruses
D. Sequence identity of subdomains of spike protein and nucleocapsid protein reflected by color (Red color indicates high sequence identity and green color indicates low sequence identity)
Figure 3

Site of B cell epitopes predicted in SARS-CoV-2 spike protein trimer A. Spike315-324(TSNFRVQPT)
highlighted in sphere in the protein structure B. Spike333-338(TNLCPF) highlighted in sphere in the protein
structure C. Spike648-663(GCLIGAEHVNNSYEC) highlighted in sphere in the protein structure D.
Spike1064-1079(HVTYVPQKENFTTAP) highlighted in sphere in the protein structure. Colors of elements
presented in the sphere of protein structure: carbon, tint; hydrogen, gray; nitrogen, blue; oxygen, red; sulfur,
yellow
Figure 4

Site of B cells discontinuous epitopes predicted through DISCOTOPE 2.0 server on the structure of SARS-CoV-2 spike protein highlighted with cartoon representation.
A

Spike_{515-338}  TSNFVQPTESIVRFPNITNLCPF
Spike_{648-663}  GCLIGAEHVNSYEC
Spike_{1064-1079}  HVTVVPAPGKNETFAP
Nucleocapsid_{61-80}  KEDLKFPRGQGVPTNSSP
Nucleocapsid_{92-117}  GKMKDLSRFWYFYLYGTGP

B

T-cell epitopes                                                                               B-cell epitopes

Pan DR epitope                                                                            Pan DR epitope
Nucleocapsid_{61-80}                                                                     Nucleocapsid_{92-117}
Spike_{315-338}                                                                          Spike_{648-663}
Spike_{1064-1079}                                                                        Spike_{1064-1079}

GPGPG linkers                                                                            (GGGGS)_2 linkers
Figure 5

Epitope based vaccine design A. B-cell epitopes (highlighted in light green color) and T-cell epitopes (highlighted in pink color) presented in the selected peptides B. Schematic view of vaccine construct

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- S1.clustalnum
- S2.clustalnum
- Nalign.clustalnum
- Salign.clustalnum
- S1.clustalnum
- S2.clustalnum
- Nalign.clustalnum
- Salign.clustalnum
- supplementaryfiguresandtables.pptx
- Bcellepitopeanimation.pptx